Loading…
Indian pharmaceutical company making branded generic medicines for cardiovascular, CNS and other chronic-disease segments, with a presence in India, Brazil and other emerging markets.
Indian pharmaceutical company making branded generic medicines for cardiovascular, CNS and other chronic-disease segments, with a presence in India, Brazil and other emerging markets.
Sells prescription brands in India, where a force of sales representatives persuades doctors to prescribe them and patients on chronic therapies buy repeat refills, plus Brazil and Germany. The Mehta family's Torrent group controls it, and in 2025 it agreed to buy control of JB Chemicals, adding to its India brands.
In one line: India's smaller branded-generics player.
Moat: narrow (brand, distribution, regulatory licence). Strong doctor/brand relationships in chronic-therapy branded generics across India and select emerging markets.
Headquarters: Ahmedabad, India · Founded: 1959 · Employees: 20,341
Size Torrent Pharmaceuticals (TORNTPHARM.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $19.1B, the 51st largest of 1,058 India companies the cockpit tracks. Shares closed at ₹4,750 on 6 Nov 2026.
Performance Over six months the shares gained 8.9%, against +4.0% for the median peer and 0.0% for the India market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 42.1% over the last twelve months (peer median +24.9%); the operating margin is 22.1% (peer median 18.2%).
Valuation It trades at 72.2× forward earnings against a peer median of 23.5× (3rd most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 38% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +27 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.7 points below its cost of capital (11.4% WACC).
Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹174B | ₹136B | ₹114B | ₹106B | ₹95.4B |
| Revenue growth | — | +20% | +7% | +11% | — |
| Gross profit | ₹80.6B | ₹58.2B | ₹51.0B | ₹46.8B | ₹39.5B |
| EBITDA | ₹57.5B | ₹42.5B | ₹36.4B | ₹33.3B | ₹28.2B |
| Net income | ₹21.2B | ₹21.6B | ₹19.1B | ₹16.6B | ₹12.5B |
| Free cash flow | n/a | ₹19.5B | ₹17.3B | ₹24.8B | ₹15.0B |
| Capital expenditure | n/a | ₹6.77B | ₹6.12B | ₹4.33B | ₹5.74B |
| Total debt | ₹141B | ₹150B | ₹32.0B | ₹40.2B | ₹53.7B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Torrent Pharmaceuticals TORNTPHARM.NS | $19.1B | +9% | +42% | 22% | 72.2× | 37.9% |
| Zydus Lifesciences ZYDUSLIFE.NS | $12.7B | +27% | +24% | 17% | 29.8× | n/a |
| Cipla CIPLA.NS | $12.1B | +4% | -1% | 13% | 29.0× | 28.2% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | $47.3B | +1% | +12% | 23% | 35.4× | 28.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TORNTPHARM.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.7% | +10.3% | 4th lowest of 21 |
| 6-month return | +8.9% | +4.0% | 9th highest of 21 |
| Distance from 52-week high | -9.5% | -10.8% | 10th highest of 21 |
| Revenue growth (TTM) | +42.1% | +24.9% | 9th highest of 21 |
| Operating margin | 22.1% | 18.2% | 10th highest of 21 |
| Forward P/E | 72.2× | 23.5× | 3rd most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 37.9% | 8.9% | 3rd most demanding of 18 |
| Growth delivered (Del g) | +11.3% | +13.1% | 7th lowest of 18 |
| Hurdle (Req g minus delivered) | +26.6 pp | -14.2 pp | 2nd most demanding of 18 |
| ROIC minus cost of capital | -1.7 pp | +7.3 pp | 6th lowest of 21 |
| EV / EBITDA | 33.3× | 17.9× | 4th most expensive of 15 |
| Net debt / EBITDA | 1.9× | -0.5× | 2nd most indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Torrent Pharmaceuticals TORNTPHARM.NS | India | $19.1B | +9% | +42% | 22% | 72.2× | 37.9% | +11.3% |
| Innovent Biologics 1801.HK | Hong Kong | $19.2B | -5% | +43% | 17% | 53.3× | 11.7% | +26.8% |
| Swedish Orphan Biovitrum SOBI.ST | Sweden | $17.6B | +13% | +15% | 30% | 25.5× | -1.1% | +13.1% |
| Alnylam Pharmaceuticals ALNY | United States | $20.9B | -47% | +56% | 20% | 22.2× | 0.9% | +49.8% |
| Exelixis EXEL | United States | $17.0B | +44% | +9% | 40% | 18.2× | -3.7% | +18.6% |
| Shionogi & 4507.T | Japan | $16.6B | -6% | +46% | 29% | 10.9× | -0.7% | +11.0% |
| Sichuan Biokin Pharmaceutical 688506.SS | China | $16.4B | -3% | +14% | -43% | n/a | n/a | n/a |
| Sigma Healthcare SIG.AX | Australia | $22.4B | -1% | +209% | 9% | 37.1× | 28.2% | +26.1% |
| Orion ORNAV.HE | Finland | $16.1B | +51% | +34% | 38% | 23.5× | -6.3% | +11.7% |
| Ascendis Pharma A/S ASND | United States | $16.0B | +8% | +128% | 10% | 40.8× | 36.4% | +152.4% |
| Viatris VTRS | United States | $22.9B | +17% | +5% | 10% | 7.5× | 12.5% | +3.7% |
| PharmaEssentia 6446.TW | Taiwan | $15.8B | +118% | +64% | 38% | 39.2× | 29.3% | +94.8% |
| Jazz Pharmaceuticals Public JAZZ | United States | $15.1B | +4% | +13% | 25% | 8.9× | -3.9% | +12.5% |
| Incyte INCY | United States | $24.4B | +21% | +25% | 12% | 15.4× | 14.2% | +14.0% |
| Ipsen IPN.PA | France | $14.7B | -4% | +14% | 30% | 10.9× | -7.3% | +7.2% |
| Yunnan Baiyao 000538.SZ | China | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% | +4.7% |
| Insmed INSM | United States | $25.1B | -16% | +240% | -42% | n/a | n/a | n/a |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | Hong Kong | $13.9B | 0% | +44% | -38% | 1,255.9× | 56.2% | +33.7% |
| Hansoh Pharma 3692.HK | Hong Kong | $26.9B | -7% | +25% | 38% | 27.5× | 8.9% | +10.8% |
| Laurus Labs LAURUSLABS.NS | India | $13.3B | +94% | +23% | 24% | 77.0× | 50.9% | +7.3% |
| Roivant Sciences ROIV | United States | $28.1B | +36% | -68% | -18,146% | n/a | n/a | n/a |